TH1901

TH1901 is an investigational **peptide-drug conjugate** developed by Theratechnologies that links **curcumin** to the proprietary SORT1-binding peptide **TH19P01**. It was designed as a **SORT1-targeted antineoplastic agent**, using sortilin-mediated internalization to selectively deliver the curcumin payload into **SORT1-expressing tumor cells**. Preclinical data described TH1901 as a proof-of-concept asset for the company's SORT1+ platform, with greater in vitro anticancer activity than unconjugated curcumin and activity in SORT1-positive colorectal cancer xenograft models. Development appears to have remained **preclinical**, and the program is best understood as an early targeted oncology conjugate rather than a marketed or clinically established therapy.